Table 1.
Characteristics and demographics at baseline.
| Ice chips (ICs) | Intraoral cooling device (ICD) | |
|---|---|---|
| Comparison group (n = 92) [%] | Test group (n = 90) [%] | |
| Sex | ||
| Male | 53 [58%] | 59 [66%] |
| Female | 39 [42%] | 31 [34%] |
| Age, years (x̄ ± SD) | 61 ± 8 | 59 ± 9 |
| Diagnoses | ||
| Multiple myeloma | 79 [85.9%] | 77 [85.6%] |
| Conditioning chemotherapy | ||
| Melphalan 140 mg/m2 | 2 [2.5%] | 2 [2.6%] |
| Melphalan 200 mg/m2 | 77 [97.5%] | 75 [97.4%] |
| Lymphoma | 13 [14.1%] | 13 [14.4%] |
| Non-Hodgkin’sa | 12 [92.3%] | 8 [61.5%] |
| Mantle Cell | 5 [41.6%] | 3 [37.5%] |
| Diffuse large B cell | 2 [16.7%] | 5 [62.5%] |
| Follicular | 3 [25.0%] | - |
| High-grade B cell | 2 [16.7%] | - |
| Hodgkin’sa | - | 2 [15.4%] |
| T cell | 1 [7.7%] | 1 [7.7%] |
| Other atypical subtypes | - | 2 [15.4%] |
| Conditioning chemotherapy | ||
| BEAC | 12 (13.0%) | 11 [12.2%] |
| BEAM | 1 (1.1%) | 2 [2.2%] |
| ASCT | ||
| I | 70 [76.1%] | 77 [85.5%] |
| II | 22 [23.9%] | 11 [12.2%] |
| III | - | 2 [2.3%] |
ASCT autologous hematopoietic stem cell transplantation (the Roman numerals refer to the number of ASCTs), x̄ mean.
High-dose chemotherapy regimens for lymphoma: BEAC (carmustine; cytarabine; etoposide; cyclophosphamide) and BEAM (carmustine; cytarabine; etoposide; melphalan).
aB-cell lymphomas.